Log in

NASDAQ:RAREUltragenyx Pharmaceutical Earnings Date, Estimates & History

$73.81
+3.32 (+4.71 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$70.20
Now: $73.81
$74.08
50-Day Range
$46.91
MA: $60.68
$72.59
52-Week Range
$31.99
Now: $73.81
$76.00
Volume482,900 shs
Average Volume581,472 shs
Market Capitalization$4.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.22

Earnings

Ultragenyx Pharmaceutical (NASDAQ:RARE) Earnings Information

Ultragenyx Pharmaceutical last announced its quarterly earnings results on May 6th, 2020. The biopharmaceutical company reported ($1.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.68) by $0.23. The firm had revenue of $36.31 million for the quarter, compared to the consensus estimate of $36.74 million. Its revenue was up 99.8% on a year-over-year basis. Ultragenyx Pharmaceutical has generated ($7.36) earnings per share over the last year. Ultragenyx Pharmaceutical has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 6th, 2020 based off prior year's report dates.

Ultragenyx Pharmaceutical Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Ultragenyx Pharmaceutical (NASDAQ:RARE) Earnings Estimates

2020 EPS Consensus Estimate: ($6.09)
2021 EPS Consensus Estimate: ($3.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20204($1.94)($1.34)($1.56)
Q2 20205($1.92)($1.30)($1.59)
Q3 20205($1.90)($1.27)($1.51)
Q4 20205($1.65)($1.25)($1.43)
Q1 20212($1.13)($1.01)($1.07)
Q2 20212($1.07)($0.95)($1.01)
Q3 20212($0.95)($0.84)($0.90)
Q4 20211($0.88)($0.88)($0.88)

Ultragenyx Pharmaceutical (NASDAQ RARE) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
8/6/2020
(Estimated)
       
5/6/20203/31/2020($1.68)($1.91)($2.03)$36.74 million$36.31 millionTranscript
2/13/2020Q4 2019($1.61)($1.62)($1.66)$32.31 million$35.59 millionTranscript
11/5/2019Q3 2019($1.71)($1.96)($1.96)$28.88 million$25.80 millionTranscript
8/1/2019Q2 2019($1.73)($1.72)($1.98)$22.16 million$24.15 millionListen
5/6/20193/31/2019($1.73)($1.82)($1.82)$18.75 million$18.17 millionListen
2/19/201912/31/2018($1.74)($1.73)($1.73)$13.30 million$16.26 millionListen
11/5/20189/30/2018($1.94)($1.74)($1.74)$11.97 million$11.80 millionListen
8/2/2018Q2 2018($2.08)($1.06)($2.68)$5.63 million$12.79 millionN/A
5/7/2018Q1 2018($0.19)$0.62$0.62$56.58 million$10.68 millionN/A
2/20/2018Q4 2017($2.00)($2.27)($2.65)$0.75 million$2.41 millionTranscript
11/2/2017Q3 2017($1.87)($1.87)($1.87)$0.02 million$0.20 millionN/A
7/27/2017Q2 2017($1.73)($1.72)($1.72)$0.01 millionN/A
5/4/2017Q1 2017($1.70)($1.63)($1.63)$0.05 millionListen
2/16/2017Q4 2016($1.74)($1.75)($1.75)$0.05 million$0.01 millionN/A
11/7/2016Q3 2016($1.56)($1.64)($1.64)$7.60 million$0.11 millionListen
8/8/2016Q2 2016($1.47)($1.46)($1.46)$0.02 millionN/A
5/9/2016Q1 2016($1.29)($1.35)($1.35)N/A
2/25/2016Q4 2015($1.11)($1.42)($1.42)Listen
11/9/2015Q3 2015($0.85)($1.03)($1.03)N/A
8/13/2015Q2 2015($0.62)($0.83)($0.83)Listen
5/11/2015Q1 2015($0.54)($0.63)($0.63)Listen
3/25/2015Q4 2014($0.53)($0.52)($0.52)Listen
11/10/2014Q3 2014($0.45)($0.50)($0.50)N/A
8/11/2014Q2 2014($0.41)($0.45)($0.45)N/A
5/12/2014Q1 2014($0.38)($0.85)($0.85)Listen
3/24/2014Q4 2013($0.34)($4.98)($4.98)N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.